A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 501–600 of 3,965
Collum, S. D., Amione‐Guerra, J., Cruz-Solbes, A. S., DiFrancesco, A., Hernandez, A. M., Hanmandlu, A., Youker, K. A., Guha, A., & Karmouty‐Quintana, H. (2017) · Canadian Respiratory Journal · doi:10.1155/2017/1430350 · Cited by 88
Bargagli, E., Piccioli, C., Rosi, E., Torricelli, E., Turi, L., Piccioli, E., Pistolesi, M., Ferrari, K., & Voltolini, L. (2019) · Pulmonology · doi:10.1016/j.pulmoe.2018.06.003 · Cited by 81
Cellular Senescence in Lung Fibrosis
Hernandez-Gonzalez, F., Faner, R., Rojas, M., Agustí, A., Serrano, M., & Sellarés, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137012 · Cited by 76
Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine
Spagnolo, P., & Cottin, V. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2016-103973 · Cited by 82
IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies
Passalacqua, G., Mincarini, M., Colombo, D., Troisi, G., Ferrari, M., Bagnasco, D., Balbi, F., Riccio, A., & Canonica, G. W. (2017) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2017.05.007 · Cited by 88
O'Brien, E. C., Durheim, M. T., Gamerman, V., Garfinkel, S., Anstrom, K. J., Palmer, S. M., & Conoscenti, C. S. (2016) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2015-000108 · Cited by 75
“1 Positive phase III trial results have been announced for nintedanib 4 and pirfenidone, 5 and in 2014, both these therapies were approved for the treatment of IPF by the US Food and Drug Administration.”
BackgroundAntifibrotic Therapies in the Liver
Schuppan, D., & Mehal, W. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550055 · Cited by 75
Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis
Su, T., Kao, J., & Liu, C. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150610578 · Cited by 80
Paulín, F., Doyle, T. J., Fletcher, E. A., Ascherman, D. P., & Rosas, I. O. (2015) · Revista de investigaci�n Cl�nica · doi:10.1016/s0034-8376(25)00249-9 · Cited by 94
The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis
Brown, A. W., & Nathan, S. D. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201703-244fr · Cited by 89
Self-citationKuse, N., Kamio, K., Azuma, A., Matsuda, K., Inomata, M., Usuki, J., Morinaga, A., Tanaka, T., Kashiwada, T., Atsumi, K., et al. (2019) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2020_87-302 · Cited by 78
Hetzel, J., Wells, A. U., Costabel, U., Colby, T. V., Walsh, S. L. F., Verschakelen, J., Cavazza, A., Tomassetti, S., Ravaglia, C., Böckeler, M., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01520-2019 · Cited by 81
Gao, J., Kalafatis, D., Carlson, L., Pesonen, I., Li, C., Wheelock, Å. M., Magnusson, J. M., & Sköld, C. M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01634-x · Cited by 79
Atypical p38 Signaling, Activation, and Implications for Disease
Burton, J. C., Antoniades, W., Okáľová, J., Roos, M., & Grimsey, N. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084183 · Cited by 80
Liu, Y., Cheng, D., Wang, Y., Xi, S., Wang, T., Sun, W., Li, G., Ma, D., Zhou, S., Li, Z., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05515-z · Cited by 89
Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis
Bando, M., Yamauchi, H., Ogura, T., Taniguchi, H., Watanabe, K., Azuma, A., Homma, S. A., & Sugiyama, Y. (2016) · Internal Medicine · doi:10.2169/internalmedicine.55.5272 · Cited by 78
Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling
Guzy, R. D., Li, L., Smith, C., Dorry, S. J., Koo, H. Y., Chen, L., & Ornitz, D. M. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.791764 · Cited by 74
MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis
Mathai, S. K., Humphries, S. M., Kropski, J. A., Blackwell, T. S., Powers, J., Walts, A. D., Markin, C. R., Woodward, J., Chung, J. H., Brown, K. K., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212430 · Cited by 83
Pirfenidone for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
Aravena, C., Gonzalo Labarca, T., Venegas, C., Arenas, Á., & Rada, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136160 · Cited by 84
Swigris, J. J., Brown, K. K., Abdulqawi, R., Buch, K. P., Dilling, D. F., Koschel, D., Thavarajah, K., Tomic, R., & Inoue, Y. (2018) · European Respiratory Review · doi:10.1183/16000617.0075-2018 · Cited by 74
Self-citationMa, X., Zhu, L., Kurche, J. S., Xiao, H., Dai, H., & Wang, C. (2020) · Thorax · doi:10.1136/thoraxjnl-2020-216732 · Cited by 89
Giacomelli, C., Piccarducci, R., Marchetti, L., Romei, C., & Martini, C. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114812 · Cited by 84
“Both drugs have been demonstrated to slow down the decline in lung function and reduce the risk of acute respiratory exacerbations in patients with IPF [107,108].”
Emerging delivery approaches for targeted pulmonary fibrosis treatment
Diwan, R., Bhatt, H., Beaven, E., & Nurunnabi, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115147 · Cited by 89
HRCT of fibrosing lung disease
Jacob, J., & Hansell, D. M. (2015) · Respirology · doi:10.1111/resp.12531 · Cited by 79
Screening for YAP inhibitors identifies statins as modulators of fibrosis
Santos, D. M., Pantano, L., Pronzati, G., Grasberger, P., Probst, C. K., Black, K. E., Spinney, J. J., Hariri, L. P., Nichols, R., Lin, Y., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0296oc · Cited by 72
Kreuter, M., Spagnolo, P., Wuyts, W. A., Renzoni, E. A., Koschel, D., Bonella, F., Maher, T. M., Kolb, M. R. J., Weycker, D. A., Kirchgässler, K.-U., et al. (2017) · Respiration · doi:10.1159/000468546 · Cited by 75
Interstitial Pneumonia With Autoimmune Features (IPAF)
Fernandes, L., Nasser, M., Ahmad, K., & Cottin, V. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00209 · Cited by 72
Studying human respiratory disease in animals – role of induced and naturally occurring models
Williams, K. J., & Roman, J. (2015) · The Journal of Pathology · doi:10.1002/path.4658 · Cited by 85
Alveolar epithelial disintegrity in pulmonary fibrosis
Kulkarni, T., de Andrade, J. A., Zhou, Y., Luckhardt, T., & Thannickal, V. J. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00115.2016 · Cited by 84
The Management of Patients With Idiopathic Pulmonary Fibrosis
Spagnolo, P., Tzouvelekis, A., & Bonella, F. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00148 · Cited by 72
“More recently, two compounds pleiotropic in their mechanisms of action—pirfenidone and nintedanib—have been approved for the treatment of IPF based on their ability to slow down the pace of functional decline and disease progression in phase 3 clinical trials (9, 10).”
BackgroundQuercetin ameliorates pulmonary fibrosis by inhibiting SphK1/S1P signaling
Zhang, X., Cai, Y., Zhang, W., & Chen, X. (2018) · Biochemistry and Cell Biology · doi:10.1139/bcb-2017-0302 · Cited by 80
“However, 50 some reagent therapies could improve pulmonary function and delay the IPF progress, such as 51 anticoagulant (Kubo et al. 2005), pirfenidone (King et al. 2014) and nintedanib (Richeldi et al. 52 2014).”
BackgroundGoldmann, T., Zissel, G., Watz, H., Drömann, D., Reck, M., Kugler, C., Rabe, K. F., & Marwitz, S. (2018) · Respiratory Research · doi:10.1186/s12931-018-0841-9 · Cited by 72
Idiopathic pulmonary fibrosis: Clinical behavior and aging associated comorbidities
Buendía-Roldán, I., Mejía, M. E., Navarro, C., & Selman, M. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.06.001 · Cited by 76
Bendstrup, E. M., Wuyts, W. A., Alfaro, T. M., Chaudhuri, N., Cornelissen, R., Kreuter, M., Nielsen, K. M., Münster, A. B., Myllärniemi, M., Ravaglia, C., et al. (2018) · Respiration · doi:10.1159/000495046 · Cited by 76
Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice
Sanders, Y. Y., Lyv, X., Zhou, Q. J., Xiang, Z., Stanford, D. D., Bodduluri, S., Rowe, S. M., & Thannickal, V. J. (2020) · JCI Insight · doi:10.1172/jci.insight.137127 · Cited by 75
Kang, J., Han, M., & Song, J. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-72607-1 · Cited by 84
Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis
Adegunsoye, A., Morisset, J., Newton, C. A., Oldham, J. M., Vittinghoff, E., Linderholm, A., Strek, M. E., Noth, I., Garcia, C. K., Wolters, P. J., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02872-2020 · Cited by 75
Immunomodulatory treatment of interstitial lung disease
van den Bosch, L., Luppi, F., Ferrara, G., & Mura, M. (2022) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666221117002 · Cited by 82
The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis
Ohta, S., Okamoto, M., Fujimoto, K., Sakamoto, N., Takahashi, K., Yamamoto, H., Kushima, H., Ishii, H., Akasaka, K., Ono, J., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174547 · Cited by 83
Role of pirfenidone in the management of pulmonary fibrosis
Meyer, K. C., & Decker, C. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s81141 · Cited by 79
The impaired proteases and anti-proteases balance in Idiopathic Pulmonary Fibrosis
Menou, A., Duitman, J., & Crestani, B. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.001 · Cited by 75
Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202405-0977oc · Cited by 70
Self-citationSakamoto, S., Muramatsu, Y., Satoh, K., Ishida, F., Kikuchi, N., Sano, G., Sugino, K., Isobe, K., Takai, Y., & Homma, S. (2015) · Respirology · doi:10.1111/resp.12477 · Cited by 70
Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis
Kondoh, Y., Cottin, V., & Brown, K. K. (2017) · European Respiratory Review · doi:10.1183/16000617.0050-2017 · Cited by 72
Idiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs
Hadjicharalambous, M. R., & Lindsay, M. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020524 · Cited by 75
“In this trial, pirfenidone was shown to slow the decline in lung function, improve exercise tolerance, and to be generally safe and well tolerated with an acceptable adverse event profile [99].”
BackgroundMedical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis
Pitre, T., Mah, J. C., Helmeczi, W., Khalid, M. F., Cui, S., Zhang, M., Husnudinov, R., Su, J. S., Banfield, L. E., Guy, B., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217976 · Cited by 72
Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review
Alsomali, H., Palmer, E., Aujayeb, A., & Funston, W. (2023) · Pulmonary Therapy · doi:10.1007/s41030-023-00216-0 · Cited by 88
Reversal of the Transcriptome by Prostaglandin E2 during Myofibroblast Dedifferentiation
Wettlaufer, S. H., Scott, J. P., McEachin, R. C., Peters-Golden, M. L., & Huang, S. K. (2015) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0468oc · Cited by 76
Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night
Schiza, S. E., Mermigkis, C. M., Margaritopoulos, G. A., Daniil, Z. D., Harari, S. A., Poletti, V. E., Renzoni, E. A., Torre, O., Visca, D., Bouloukaki, I., et al. (2015) · European Respiratory Review · doi:10.1183/16000617.00009114 · Cited by 76
IPF clinical trial design and endpoints
Nathan, S. D., & Meyer, K. C. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000091 · Cited by 72
Self-citationKreuter, M., Wijsenbeek, M. S., Vasakova, M., Spagnolo, P., Kolb, M., Costabel, U., Weycker, D., Kirchgaessler, K.-U., & Maher, T. M. (2016) · European Respiratory Journal · doi:10.1183/13993003.02087-2015 · Cited by 70
Understanding COPD-overlap syndromes
Poh, T. Y., Aogáin, M. M., Chan, A., Yii, A. C. A., Yong, V. F. L., Tiew, P. Y., Koh, M. S., & Chotirmall, S. H. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1305895 · Cited by 76
The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis
Schuliga, M. J., Grainge, C., Westall, G. P., & Knight, D. A. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.02.016 · Cited by 73
The Objective Identification and Quantification of Interstitial Lung Abnormalities in Smokers
Ash, S. Y., Harmouche, R., Ross, J. C., Díaz, A. A., Hunninghake, G. M., Putman, R. K., Onieva, J. O., Martínez, F. J., Choi, A. M. K., Lynch, D. A., et al. (2016) · Academic Radiology · doi:10.1016/j.acra.2016.08.023 · Cited by 70
Naringenin: A Promising Therapeutic Agent against Organ Fibrosis
Du, Y., Ma, J., Fan, Y., Wang, X., Zheng, S., Feng, J., Li, J., Fan, Z., Li, G., & Ye, Q. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/1210675 · Cited by 72
WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts
Klee, S., Lehmann, M., Wagner, D. E., Baarsma, H. A., & Königshoff, M. (2016) · Scientific Reports · doi:10.1038/srep20547 · Cited by 69
Li, G., Ren, J., Hu, Q., Deng, Y., Chen, G., Guo, K., Li, R., Li, Y., Wu, L., Wang, G., et al. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.08.002 · Cited by 69
Rowbottom, M. W., Bain, G., Calderon, I., Lasof, T., Lonergan, D. G., Lai, A. G., Huang, F., Darlington, J. V., Prodanovich, P., Santini, A. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00345 · Cited by 71
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis
Brownell, R., Kaminski, N., Woodruff, P. G., Bradford, W. Z., Richeldi, L., Martinez, F. J., & Collard, H. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0169ci · Cited by 68
“Recently, two medications, nintedanib and pirfenidone, have been approved for the treatment of IPF based on reductions in the rate of physiologic decline, but the disease still progresses in treated patients and there remains no cure (5, 6).”
BackgroundSelf-citationWestra, I. M., Mutsaers, H. A. M., Luangmonkong, T., Hadi, M., Oosterhuis, D., de Jong, K. P., Groothuis, G. M. M., & Olinga, P. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.05.012 · Cited by 75
Heukels, P., van Hulst, J. A. C., van Nimwegen, M., Boorsma, C. E., Melgert, B. N., von der Thüsen, J. H., van den Blink, B., Hoek, R. A. S., Miedema, J., Neys, S. F. H., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1195-7 · Cited by 80
for the EMPIRE registry, Tran, T., Šterclová, M., Moğulkoç, N., Lewandowska, K. B., Müller, V., Hájková, M., Kramer, M. R., Jovanović, D., Tekavec-Trkanjec, J., et al. (2020) · Respiratory Research · doi:10.1186/s12931-019-1271-z · Cited by 79
Emerging Roles of Airway Epithelial Cells in Idiopathic Pulmonary Fibrosis
Chakraborty, A., Mastalerz, M., Ansari, M., Schiller, H. B., & Staab-Weijnitz, C. A. (2022) · Cells · doi:10.3390/cells11061050 · Cited by 68
Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study
Lee, J. H., Park, H. J., Kim, S., Kim, Y., & Kim, H. C. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02340-8 · Cited by 72
Update on therapeutic management of idiopathic pulmonary fibrosis
Spagnolo, P., Τzouvelekis, Α., & Bonella, F. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s69716 · Cited by 78
“In fact, since the publication of the most recent IPF guidelines, two compounds, ie, pirfenidone and nintedanib, have consistently proven effective in reducing functional decline and disease progression, 15,16 and are likely to become the standard of care worldwide in the near future.”
A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis
Huang, Y., Ma, S., Vij, R., Oldham, J. M., Herazo‐Maya, J. D., Broderick, S. M., Strek, M. E., White, S. R., Hogarth, D. K., Sandbo, N. K., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0142-8 · Cited by 77
Rajala, K., Lehto, J. T., Sutinen, E., Kautiainen, H., Myllärniemi, M., & Saarto, T. H. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0738-x · Cited by 75
Danazol Treatment for Telomere Diseases
Townsley, D. M., Bogdan, D., & Young, N. S. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1607752 · Cited by 74
Intestinal fibrosis: ready to be reversed
Latella, G., & Rieder, F. (2017) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000363 · Cited by 76
Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis
Griffiths, K. R., Habiel, D. M., Jaffar, J., Binder, U., Darby, W. G., Hosking, C. G., Skerra, A., Westall, G. P., Hogaboam, C. M., & Foley, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-20811-5 · Cited by 78
Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis
Jessen, H., Hoyer, N., Prior, T. S., Frederiksen, P., Karsdal, M. A., Leeming, D. J., Bendstrup, E., Sand, J. M. B., & Shaker, S. B. (2021) · Respiratory Research · doi:10.1186/s12931-021-01801-0 · Cited by 65
Gu, Y., Lawrence, T., Mohamed, R., Liang, Y., & Yahaya, B. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923235 · Cited by 77
“Although two drugs, namely Nintedanib and Pirfenidone, are recognised as effective therapies for this disease (9, 10), they only alleviate disease progression and do not address damage that has already occurred.”
BackgroundKhor, Y. H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201611-934oc · Cited by 69
Wu, A. C., Kiley, J. P., Noel, P. J., Amur, S., Burchard, E. G., Clancy, J. P., Galanter, J., Inada, M., Jones, T. K., Kropski, J. A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1895st · Cited by 67
Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis
Barnes, J. W., Duncan, D., Helton, S., Hutcheson, S. B., Kurundkar, D., Logsdon, N. J., Locy, M. L., Garth, J. M., Denson, R. S., Farver, C. F., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00246.2018 · Cited by 72
Buono, M. G. D., Iannaccone, G., Scacciavillani, R., Carbone, S., Camilli, M., Niccoli, G., Borlaug, B. A., Lavie, C. J., Arena, R. A., Crea, F., et al. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.011 · Cited by 73
Karampitsakos, Τ., Torrisi, S. E., Antoniou, K. M., Manali, E. D., Korbila, I. P., Παπαϊωάννου, Ο., Sampsonas, F., Katsaras, M., Vasarmidi, E., Papakosta, D., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01725-9 · Cited by 76
Antar, S. A., Saleh, M. A., & Al-Karmalawy, A. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121048 · Cited by 76
Targeting extracellular matrix stiffness for cancer therapy
Feng, X., Cao, F., Wu, X., Xie, W., Wang, P., & Jiang, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1467602 · Cited by 87
Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations
Jo, H. E., Randhawa, S., Corte, T. J., & Moodley, Y. P. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0366-1 · Cited by 79
Epigenetics in lung fibrosis: from pathobiology to treatment perspective
Helling, B. A., & Yang, I. V. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000191 · Cited by 70
The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis
Kurowska‐Stolarska, M., Hasoo, M. K., Welsh, D., Stewart, L., McIntyre, D., Morton, B. E., Johnstone, S. A., Miller, A. M., Asquith, D. L., Millar, N. L., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.021 · Cited by 66
German Guideline for Idiopathic Pulmonary Fibrosis – Update on Pharmacological Therapies 2017
Behr, J., Günther, A., Bonella, F., Geissler, K. H., Koschel, D., Kreuter, M., Prasse, A., Schönfeld, N., Sitter, H., Müller–Quernheim, J., et al. (2018) · Pneumologie · doi:10.1055/s-0043-123035 · Cited by 71
Li, X., Yan, X., Wang, Y., Wang, J., Zhou, F., Wang, H., Xie, W., & Kong, H. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.12.013 · Cited by 68
Stem cell-based therapy for pulmonary fibrosis
Cheng, W., Zeng, Y., & Wang, D. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03181-8 · Cited by 65
Delanote, I., Wuyts, W. A., Yserbyt, J., Verbeken, E. K., Verleden, G. M., & Vos, R. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0308-z · Cited by 65
Artigas, L., Coma, M., Matos‐Filipe, P., Aguirre‐Plans, J., Farrés, J., Valls, R., Fernández‐Fuentes, N., de la Haba-Rodríguez, J., Olvera, À., Barberá, J. M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240149 · Cited by 75
“Pirfenidone has also been described as antifibrotic, reducing the rate of lung damage by 50% in patients with idiopathic pulmonary fibrosis [68].”
BackgroundNandy, S., Raphaely, R. A., Muniappan, A., Shih, A. R., Roop, B. W., Sharma, A., Keyes, C. M., Colby, T. V., Auchincloss, H. G., Gaissert, H. A., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202104-0847oc · Cited by 71
Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis
Maher, T. M., Avram, C., Bortey, E., Hart, S. P., Hirani, N., Molyneux, P. L., Porter, J. C., Smith, J. A., & Sciascia, T. R. (2023) · NEJM Evidence · doi:10.1056/evidoa2300083 · Cited by 76
Zhou, B., Liu, H., Xu, F., & Jia, X. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01557-2 · Cited by 84
Ohkubo, H., Kanemitsu, Y., Uemura, T., Takakuwa, O., Takemura, M., Maeno, K., Ito, Y., Oguri, T., Kazawa, N., Mikami, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0152505 · Cited by 77
Guan, R., Wang, X., Zhao, X., Song, N., Zhu, J., Wang, J., Wang, J., Xia, C., Chen, Y., Zhu, D., et al. (2016) · Scientific Reports · doi:10.1038/srep35696 · Cited by 67
Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis
Komiya, C., Tanaka, M., Tsuchiya, K., Shimazu, N., Mori, K., Furuke, S., Miyachi, Y., Shiba, K., Yamaguchi, S., Ikeda, K., et al. (2017) · Scientific Reports · doi:10.1038/srep44754 · Cited by 70
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.017 · Cited by 69
Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension
Bellaye, P., Yanagihara, T., Granton, E., Sato, S., Shimbori, C., Upagupta, C., Imani, J., Hambly, N., Ask, K., Gauldie, J., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01857-2017 · Cited by 72
Available Therapeutic Options for Corneal Neovascularization: A Review
Drzyzga, Ł. R., Śpiewak, D., Dorecka, M., & Wyględowska‐Promieńska, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105479 · Cited by 89
“Pirfenidone might prevent excessive scarring by inhibiting fibroblast proliferation and collagen synthesis [100–103].”
BackgroundO’Dwyer, D. N., Norman, K. C., Xia, M., Huang, Y., Gurczynski, S. J., Ashley, S. L., White, E. S., Flaherty, K. R., Martínez, F. J., Murray, S., et al. (2017) · Scientific Reports · doi:10.1038/srep46560 · Cited by 72
Bergeron, A., & Cheng, G. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.07.003 · Cited by 64
Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort
Adegunsoye, A., Oldham, J. M., Chung, J. H., Montner, S. M., Lee, C. T., Witt, L. J., Stahlbaum, D., Bermea, R. S., Chen, L. W., Hsu, S., et al. (2017) · CHEST Journal · doi:10.1016/j.chest.2017.09.026 · Cited by 67
Nolan, C. M., Birring, S. S., Maddocks, M. M., Maher, T. M., Patel, S., Barker, R. E., Jones, S. E., Walsh, J. A., Wynne, S. C., George, P. M., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.00281-2019 · Cited by 65
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.